Silence Therapeutics PLC (SLN)

NASDAQ: SLN · IEX Real-Time Price · USD
10.43
+0.44 (4.40%)
Aug 8, 2022 4:30 PM EDT - Market closed
4.40%
Market Cap 2.80B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 268.30M
EPS (ttm) -1.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 82,000
Open 10.36
Previous Close 9.99
Day's Range 10.01 - 11.51
52-Week Range 7.80 - 26.84
Beta 0.50
Analysts n/a
Price Target 39.35 (+277.3%)
Earnings Date n/a

About SLN

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-as... [Read more...]

Industry Biotechnology
CEO David Solomon
Employees 105
Stock Exchange NASDAQ
Ticker Symbol SLN
Full Company Profile

Financial Performance

In 2021, SLN's revenue was $12.42 million, an increase of 126.59% compared to the previous year's $5.48 million. Losses were -$39.41 million, 21.1% more than in 2020.

Financial Statements

News

Silence Therapeutics to Present at Jefferies Healthcare Conference

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) thera...

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) thera...

Silence Therapeutics Reports First Quarter 2022 Results

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) thera...

Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of...

Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) thera...

Silence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results Fr...

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) thera...

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Br...

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) thera...

Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501

LONDON & DUBLIN--(BUSINESS WIRE)--Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the tre...

Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results

LONDON--(BUSINESS WIRE)---- $SLN #earnings--Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results

Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022

LONDON--(BUSINESS WIRE)---- $SLN #earnings--Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022

Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (“siRNA”) the...

Silence Therapeutics Posts First Human Data For Cardiovascular Candidate

Silence Therapeutics plc SLN showed that its RNAi technology could reduce a patient's lp(a) levels by 98% at a high dose. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults ...

LONDON--(BUSINESS WIRE)---- $SLN #SilenceisGOLDen--Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)

Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at the American College of...

LONDON--(BUSINESS WIRE)---- $SLN #ACC22--Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at ACC Meeting in April 2022.

Silence Therapeutics' Head of Molecular Design Dr. Marie Wikström Lindholm Appointed to Oligonucleotide Therapeutics ...

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Dr. Marie Wikström Lindholm, SVP, Molecular Design at Silence Therapeutics, elected to Board of Directors of Oligonucleotide Therapeutics Society.

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference

New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases

New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases

Silence Therapeutics Welcomes Deep Track Capital as New Shareholder

1 December 2021

Silence Therapeutics Begins Exclusive Nasdaq Trading

Silence Therapeutics Begins Exclusive Nasdaq Trading

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder

Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder

Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day

Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day

Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its P...

Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market

Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence's mRNAi GOLD...

Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence's mRNAi GOLD™ Platform

Silence Therapeutics to Host R&D Day on October 21, 2021

Silence Therapeutics to Host R&D Day on October 21, 2021